ADC Therapeutics SA (ADCT) vs Cardiol Therapeutics (CRDL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 24.5% versus a loss of 67.1%. Over five years, CRDL leads with a -66.4% price change compared with -94.4% for ADCT. ADC Therapeutics SA is the larger company by market cap ($181.3 million vs $160.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | CRDL |
|---|---|---|
| Share price | $1.42 | $1.32 |
| Market cap | $181.29M | $160.40M |
| 1-day change | +11.81% | +0.76% |
| YTD return | -59.77% | +38.36% |
| 1-year return | -67.05% | +24.53% |
| 5-year return | -94.42% | -66.41% |
| EPS (TTM) | $-0.60 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $2.34 |
| 52-week low | $0.78 | $0.88 |
| Distance from 52-week high | -71.49% | -43.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +134.51% | +533.33% |
| Average volume | 1.34M | 1.39M |
| Shares outstanding | 127.67M | 121.51M |
| Employees | 188 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed ADCT by 91.6 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
ADCT vs CRDL FAQ
Which is bigger, ADC Therapeutics SA or Cardiol Therapeutics?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $181.29M compared with $160.40M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, ADCT or CRDL?
CRDL returned +24.53% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Cardiol Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ADC Therapeutics SA and Biotechnology: Biological Products (No Diagnostic Substances) for Cardiol Therapeutics.